Pharmaceutical Manufacturing News and Research

RSS

ABT Molecular Imaging secures $9 million through its Series A financing

ABT Molecular Imaging, a medical imaging company developing a production platform to generate unit doses of molecular imaging drugs, announced today it has secured a $9 million round of financing.

7 Oct 2009

CDC Software expands operations in China, adds seven resellers

CDC Software Corporation, a global provider of enterprise software applications and services, today announced it has added seven resellers to its Global Partner Program as part of its previously announced expansion plans to position China as the second largest market, in terms of revenue, for the company in the next few years.

1 Oct 2009

Caraco enters into a consent decree with the FDA regarding its drug manufacturing operations

Caraco Pharmaceutical Laboratories, Ltd. announced today that it has entered into a consent decree with the U.S. Food and Drug Administration (FDA) regarding the company's drug manufacturing operations. The decree provides a series of measures that, when satisfied, will permit Caraco to resume manufacturing and distributing those products that are manufactured in its Detroit area facilities.

30 Sep 2009

Opinion: 'Microland' to fight poverty; ensuring quality, timely drugs for Africa

In a Forbes column, Elisabeth Eaves, deputy editor at Forbes, examines the concept of "'microland:' securing rights to small plots of land for the world's poorest."

30 Sep 2009

H1N1 influenza pandemic could present a host of medical ethics issues: JCB

The anticipated onset of a second wave of the H1N1 influenza pandemic could present a host of thorny medical ethics issues best considered well in advance, according to the University of Toronto Joint Centre for Bioethics, which today released nine papers for public discussion.

25 Sep 2009

Dalton Pharma expands pharmaceutical manufacturing services

Dalton Pharma Services is pleased to announce the expansion of its pharmaceutical manufacturing services by adding Formulation Development to its list of integrated capabilities.

22 Sep 2009

Cydex Pharmaceuticals announces extension of agreement with Hovione

CyDex Pharmaceuticals, Inc. today announced the extension of its relationship with Hovione SA as the company’s exclusive supplier of Captisol® for an additional five years.

21 Sep 2009

Pharmacyclics announces financial results for fourth quarter and FY 2009

Pharmacyclics, Inc. today reported financial results for its fourth quarter and fiscal year ended June 30, 2009. During the fourth quarter of fiscal 2009 Pharmacyclics incurred a GAAP net loss of $5.4 million, or $0.20 per share, compared to a net loss of $4.6 million, or $0.18 per share for the fourth quarter of fiscal 2008.

18 Sep 2009

Opinion: Local drug production in developing countries; Obama's PEPFAR changes

The international community focuses on lowering drug prices as a means of improving access and "today its idea is local pharmaceutical production .

5 Sep 2009

Lonza submits non-binding proposal to buy all of outstanding restricted voting shares of Patheon

The Special Committee of Independent Directors of Patheon Inc. (TSX:PTI) and Lonza Group AG (SIX:LONN) announced today that Lonza, one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries, has submitted a non-binding proposal to acquire all of the outstanding Restricted Voting Shares of Patheon at a price of US$3.55 per Restricted Voting Share.

21 Aug 2009

WHO Director-General, other officials visit Uganda to assess malaria control efforts

WHO Director-General Margaret Chan arrived in Uganda on Wednesday for a three-day working visit to examine the country's progress on the prevention, control and treatment of malaria, the Monitor reports. Ray Chambers, the U.N. special envoy for malaria, and Tadataka Yamada, president of the Bill & Melinda Gates Foundation's Global Health Program, are traveling with Chan.

20 Aug 2009

Supplemental Manufacturing and Ingredients forges manufacturing agreement with HealthSport's subsidiary, InnoZen

InnoZen, Inc., a wholly owned subsidiary of HealthSport, Inc. (OTC Bulletin Board: HSPO) announced today that it has entered into a manufacturing agreement with Supplemental Manufacturing and Ingredients, LLC ("SMI"), a cGMP certified manufacturer based in Tempe, Arizona. As part of the Agreement, SMI has committed to purchasing $1,000,000 worth of HealthSport common stock.

20 Aug 2009

Synco Bio to manufacture Versartis type 2 diabetes drug candidate

SynCo Bio Partners, a Netherlands based biopharmaceutical contract manufacturer, and Versartis, Inc. today announced a strategic partnership to produce Versartis' lead drug candidate VRS-859, a novel GLP-1 analog for monthly dosing to treat type 2 diabetes Under the agreement, SynCo will further develop the Versartis existing production process for VRS-859 and optimize the manufacturing process to increase yields for the forthcoming cGMP production.

18 Aug 2009

Aryx Therapeutics reports Q2 2009 financials

ARYx Therapeutics, Inc. (NASDAQ:ARYX) today reported results of operations and provided a general business update for the second quarter ended June 30, 2009.

13 Aug 2009

Schering-Plough announces agreement with Orchid Chemicals & Pharmaceuticals on generic forms of CLARINEX

Schering-Plough Corporation (NYSE: SGP) today announced an agreement with Orchid Chemicals & Pharmaceuticals Ltd. and Orgenus Pharma, Inc. ("Orchid"), related to the generic manufacturing of certain formulations of CLARINEX(R) (desloratadine).

12 Aug 2009

Mylan receives FDA approval for generic Imitrex

Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Sumatriptan Succinate Tablets, 25 mg (base), 50 mg (base) and 100 mg (base). This product is manufactured in Mylan's Morgantown, W.Va. facility.

10 Aug 2009

Swine Flu - getting drugs to the market more rapidly

The pharmaceutical industry has been up in arms this year. Giants such as Pfizer, GSK and AstraZeneca are looking for deals in the downturn whilst competing against increasing generic competition as some of the best selling medicines are coming off patent. In addition to the sectors ever-changing landscape companies are under tremendous pressure from governments to combat the Swine flu pandemic that has gripped the world.

29 Jul 2009

Antisense Therapeutics trial of ATL1101 in prostate cancer shows promise

Antisense Therapeutics Ltd. (ASX: ANP) has reported further positive results from its collaborative preclinical research studies on the therapeutic potential of ATL1101 in prostate cancer. In experimental models, ATL1101 treatment significantly enhanced the tumor-suppressive effect of the cancer drug Paclitaxel. Paclitaxel is one of a class of drugs known as taxanes.

18 Jun 2009

Using combinatorial libraries to engineer genetic circuits advances synthetic biology

Streamlining the construction of synthetic gene networks has led a team of Boston University researchers to develop a technique that couples libraries of diversified components with computer modeling to guide predictable gene network construction without the back and forth tweaking.

22 Apr 2009

Experts discuss disease-fight dollars for developing world

The debate over how to spend the hundreds of millions of dollars earmarked to fight AIDS and other killer diseases in developing countries will come under the spotlight at a meeting of international experts.

5 Apr 2009